52X.F MAGLE CHEMOSWED HOLDING
- Market cap
- EUR 196K
- P/E
- -
- P/B
- 0.02x
- ROE
- -29.9%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is 52X.F undervalued?
Graham numberThe Graham number of MAGLE CHEMOSWED HOLDING cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
MAGLE CHEMOSWED HOLDING fundamental analysis
No fundamental analysis for MAGLE CHEMOSWED HOLDING yet.
MAGLE CHEMOSWED HOLDING stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About MAGLE CHEMOSWED HOLDING
Magle Chemoswed Holding AB (publ) engages in researching, developing, and manufacturing in the areas of medicinal chemistry and pharmaceutical technology in Sweden, Switzerland, rest of Europe, the United States, Brazil, and internationally. It offers degradable starch microsphere and dextran products; and active pharmaceutical ingredients, as well as engages in the research, development, manufacture, market, and sale of diagnostics products to hospitals, clinics, and pharma…
Full company profileMAGLE CHEMOSWED HOLDING financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
MAGLE CHEMOSWED HOLDING annual financial statements (SEK; K = thousand, M = million, B = billion, T = trillion)
| Item | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|
| Income Statement | ||||||
| Revenue | 132M | 146M | 170M | 236M | 268M | 283M |
| Gross Profit | 111M | 134M | 154M | 222M | 203M | 268M |
| Operating Income | 5.02M | 14.8M | 18.4M | 8.90M | -235M | -71.3M |
| EBITDA | - | 25.8M | 31.4M | 59.2M | -55.8M | -8.42M |
| Net Income | 4.28M | 9.15M | 12.2M | 6.27M | -252M | -78.0M |
| EPS | 0.39 | 0.84 | 1.12 | 0.31 | -12 | -3.78 |
| Balance Sheet | ||||||
| Total Assets | 244M | 253M | 273M | 1.09B | 911M | 813M |
| Total Liabilities | 105M | 106M | 115M | 532M | 515M | 553M |
| Shareholders' Equity | 139M | 147M | 158M | 561M | 396M | 260M |
| Cash & Short-term Investments | 3.99M | 9.88M | 7.08M | 2.72M | 13.6M | 2.09M |
| Cash Flow | ||||||
| Operating Cash Flow | 26.0M | 12.5M | 15.3M | -11.7M | -48.0M | -104M |
| Capital Expenditure | 11.8M | 16.9M | 15.1M | 16.1M | 20.0M | 0.00 |
| Free Cash Flow | 14.2M | -4.41M | 209K | -27.8M | -68.0M | -104M |
| Ratios | ||||||
| ROE | 3.1% | 6.2% | 7.7% | 1.1% | -63.6% | -29.9% |
| ROA | 1.8% | 3.6% | 4.5% | 0.6% | -27.6% | -9.6% |
| Net Profit Margin | 3.2% | 6.3% | 7.1% | 2.7% | -93.9% | -27.5% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
MAGLE CHEMOSWED HOLDING dividends
MAGLE CHEMOSWED HOLDING has not paid dividends in the last 5 fiscal years.
Who owns MAGLE CHEMOSWED HOLDING
- Insiders 0.00%
- Institutions 27.34%
- Public & others 72.66%
- Shares outstanding 20.6M
- Free float 14.7M
MAGLE CHEMOSWED HOLDING company profile
- Company name
- MAGLE CHEMOSWED HOLDING
- Ticker
- 52X.F
- ISIN
- SE0014401014
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 150
- Fiscal year end
- December
- Address
- Agneslundsvägen 27, Malmö, Sweden, 212 15
- Phone
- 46 76 164 33 12
- Website
- maglegroup.com
About MAGLE CHEMOSWED HOLDING
Magle Chemoswed Holding AB (publ) engages in researching, developing, and manufacturing in the areas of medicinal chemistry and pharmaceutical technology in Sweden, Switzerland, rest of Europe, the United States, Brazil, and internationally. It offers degradable starch microsphere and dextran products; and active pharmaceutical ingredients, as well as engages in the research, development, manufacture, market, and sale of diagnostics products to hospitals, clinics, and pharmacies; and contract development and manufacturing organization activities. The company also provides warfarin sodium products used as anticoagulants for multiple indications; melperone hydrochloride, an antipsychotic agent; and isradipine, a calcium channel blocker used to treat hypertension. In addition, it offers EmboCept S, a microsphere-based medical device used in vascular occlusion of liver and lung tumors; SmartGel, a non-allergenic hydrogel based on the company's microsphere technology; and SmartPAN, a medical device for the detection of pancreatic fluid leakage during open or minimally invasive surgical procedures. Further, the company is developing EmboCept M for the treatment of benign prostatic hyperplasia; EmboCept L for the treatment of uterine fibroids; SmartGel II, an advanced wound care hydrogel for the removal and prevention of wound biofilm; and SmartBone, an advanced formulation of microspheres in combination with active ingredients for stimulation of bone growth in surgical implant procedures. Additionally, it develops and produces stem cell-based therapies for investigational and GMP use; and provides consulting services in materials and solid phase analysis services. Magle Chemoswed Holding AB (publ) was founded in 1944 and is based in Malmö, Sweden.
MAGLE CHEMOSWED HOLDING management
1- Mr. Aaron WongCFO & CEO · born 1984